At Taiho Pharma Canada, Inc., all of our efforts are guided by our corporate philosophy: “We strive to improve human health and contribute to a society enriched by smiles.” To that end, we are currently researching and developing a number of innovative oral anti-cancer therapies. Please view our Pipeline page to learn more about the investigational products being studied in the United States, Canada and around the world.
We are pleased to announce that PrLONSURF® (trifluridine and tipiracil) is now available in Canada as of January 23, 2018.
Canadian regulations limit the scope of information we are permitted to give on prescription drugs via the internet or other means.
To learn more about LONSURF, please visit the links below:
We are pleased to announce that PrINQOVI® (decitabine and cedazuridine tablets) is now available in Canada as of July 7, 2020.
Canadian regulations limit the scope of information we are permitted to give on prescription drugs via the internet or other means.
To learn more about INQOVI, please visit the links below
Please consult a qualified health professional for more detailed information.
Please refer to the Health Canada Website for Health Canada Advisories and Warnings.